The objective of this study was to determine long-term immunity to hepatitis B virus (HBV) in a cohort of adolescents who received plasma-derived HBV vaccine in 1989 and 1990 in a remote Australian Aboriginal community. This was done using a serological survey; primary outcome measures were cut-off titres of HBsAb, and the presence of HBcAb and/or HBsAg. Of 37 adolescents in the cohort, 4 (11%) had evidence of active infection, one with abnormal liver enzymes, 7 (19%) had evidence of past infection, 15 (41%) were HBsAb positive in low titre and 11 (30%) were classed as immune. It was concluded that there was relatively poor long-term serological immunity to HBV vaccination in this group; a finding which is in keeping with similar studies in...
Objective: To quantify the disparity in incidence of hepatitis B between indigenous and non-indigeno...
In Australia's Northern Territory, the hepatitis B virus (HBV) subgenotype A2 (subtype adw2) vaccine...
To determine the duration of protection from hepatitis B vaccine given in infancy and early childhoo...
The objective of this study was to determine long-term immunity to hepatitis B virus (HBV) in a coho...
The objective of this study was to determine long-term immunity to hepatitis B virus (HBV) in a coho...
From August 1989 to may 1993, extensive studies on the epidemiology of hepatitis B virus (HBV) infec...
Abstract Background Chronic hepatitis B is a public health concern in Aboriginal communities in the ...
Background A higher prevalence of chronic hepatitis B (CHB) has been reported in Aboriginal and Torr...
BACKGROUND: Aboriginal and Torres Strait Islander people are disproportionately affected by hepatiti...
BACKGROUND: In Australia, higher rates of chronic hepatitis B (HBsAg) have been reported among Abori...
BACKGROUND: Indigenous populations globally are disproportionately affected by chronic hepatitis B v...
A national vaccination program against hepatitis B virus (HBV) to immunize every newborn was initiat...
Objective: Hepatitis B virus (HBV) infection remains an important cause of morbidity and mortality i...
The Australian National Hepatitis B Strategy 2010-13 outlines five priority areas for developing a c...
To determine the duration of protection from hepatitis B vaccine given in infancy and early childhoo...
Objective: To quantify the disparity in incidence of hepatitis B between indigenous and non-indigeno...
In Australia's Northern Territory, the hepatitis B virus (HBV) subgenotype A2 (subtype adw2) vaccine...
To determine the duration of protection from hepatitis B vaccine given in infancy and early childhoo...
The objective of this study was to determine long-term immunity to hepatitis B virus (HBV) in a coho...
The objective of this study was to determine long-term immunity to hepatitis B virus (HBV) in a coho...
From August 1989 to may 1993, extensive studies on the epidemiology of hepatitis B virus (HBV) infec...
Abstract Background Chronic hepatitis B is a public health concern in Aboriginal communities in the ...
Background A higher prevalence of chronic hepatitis B (CHB) has been reported in Aboriginal and Torr...
BACKGROUND: Aboriginal and Torres Strait Islander people are disproportionately affected by hepatiti...
BACKGROUND: In Australia, higher rates of chronic hepatitis B (HBsAg) have been reported among Abori...
BACKGROUND: Indigenous populations globally are disproportionately affected by chronic hepatitis B v...
A national vaccination program against hepatitis B virus (HBV) to immunize every newborn was initiat...
Objective: Hepatitis B virus (HBV) infection remains an important cause of morbidity and mortality i...
The Australian National Hepatitis B Strategy 2010-13 outlines five priority areas for developing a c...
To determine the duration of protection from hepatitis B vaccine given in infancy and early childhoo...
Objective: To quantify the disparity in incidence of hepatitis B between indigenous and non-indigeno...
In Australia's Northern Territory, the hepatitis B virus (HBV) subgenotype A2 (subtype adw2) vaccine...
To determine the duration of protection from hepatitis B vaccine given in infancy and early childhoo...